Reuters -- British inhaled drug specialist Vectura reported a bigger-than-expected rise in full-year revenue and a smaller loss, and said on Tuesday two key new drugs were set to enter final-stage clinical tests.
Reuters -- British inhaled drug specialist Vectura reported a bigger-than-expected rise in full-year revenue and a smaller loss, and said on Tuesday two key new drugs were set to enter final-stage clinical tests.
